FibroBiologics Completes Manufacturing of Third Batch of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial

Phase 1CYWC628Positive

AI Analysis

Summary

FibroBiologics completed manufacturing of the third batch of CYWC628 drug product for its Phase 1/2 diabetic foot ulcer clinical trial, with existing supply expected to be sufficient to complete the study while generating cost savings.

Clinical Trial Data

Phase

Phase 1/2

Outcome Details

Third batch of drug product manufactured for Phase 1/2 clinical trial

Importance:3/10

Sentiment:

0.40

manufacturingclinical-trialcost-savingsdrug-product

Related Companies

$FBLG

Read the original article

Published by PR Newswire Biotech on July 7, 2026 12:30 PM

Read Original